Investment analysts at HC Wainwright initiated coverage on shares of Innoviva (NASDAQ:INVA - Get Free Report) in a note issued to investors on Monday, Marketbeat reports. The firm set a "buy" rating and a $40.00 price target on the biotechnology company's stock. HC Wainwright's price target would suggest a potential upside of 103.98% from the stock's previous close. HC Wainwright also issued estimates for Innoviva's Q2 2025 earnings at $0.57 EPS, Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.82 EPS, Q1 2026 earnings at $0.55 EPS, Q2 2026 earnings at $0.68 EPS, Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $2.74 EPS.
Other equities research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Innoviva from a "hold" rating to a "buy" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald began coverage on shares of Innoviva in a research report on Friday, July 11th. They set an "overweight" rating and a $26.00 price target on the stock.
View Our Latest Report on INVA
Innoviva Stock Down 1.4%
NASDAQ INVA traded down $0.27 on Monday, reaching $19.61. The company had a trading volume of 352,519 shares, compared to its average volume of 712,948. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -19.43 and a beta of 0.37. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.30 and a current ratio of 2.48. Innoviva has a 1-year low of $16.67 and a 1-year high of $22.00. The company's fifty day moving average is $19.89 and its 200-day moving average is $18.64.
Innoviva (NASDAQ:INVA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter. Innoviva had a negative net margin of 16.15% and a positive return on equity of 15.77%. The firm had revenue of $88.63 million during the quarter. On average, research analysts forecast that Innoviva will post 0.33 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Innoviva
A number of institutional investors and hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue raised its holdings in shares of Innoviva by 7.7% in the 2nd quarter. State of Alaska Department of Revenue now owns 32,874 shares of the biotechnology company's stock valued at $659,000 after purchasing an additional 2,349 shares during the period. Ballentine Partners LLC bought a new stake in shares of Innoviva in the 2nd quarter valued at about $350,000. GAMMA Investing LLC raised its holdings in shares of Innoviva by 58.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,146 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 2,648 shares during the period. Exchange Traded Concepts LLC raised its holdings in shares of Innoviva by 2.8% in the 2nd quarter. Exchange Traded Concepts LLC now owns 180,982 shares of the biotechnology company's stock valued at $3,636,000 after purchasing an additional 4,957 shares during the period. Finally, Parallel Advisors LLC raised its holdings in shares of Innoviva by 157.5% in the 2nd quarter. Parallel Advisors LLC now owns 1,849 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 1,131 shares during the period. 99.12% of the stock is owned by institutional investors.
Innoviva Company Profile
(
Get Free Report)
Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Further Reading
Before you consider Innoviva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innoviva wasn't on the list.
While Innoviva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
